Athenex has filed a patent for a method of treating angiosarcoma using a combination of orally administered paclitaxel and a P-gp inhibitor. The method aims to reduce negative outcomes associated with intravenous paclitaxel therapy. The patent claims the specific dosage and administration schedule for the treatment. GlobalData’s report on Athenex gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Athenex, cancer treatment biomarkers was a key innovation area identified from patents. Athenex's grant share as of June 2023 was 1%. Grant share is based on the ratio of number of grants to total number of patents.
Pharmaceutical combination for treating angiosarcoma with oral paclitaxel
A recently filed patent (Publication Number: US20230181566A1) describes a method for treating angiosarcoma, a type of cancer that forms in the lining of blood vessels. The method involves the oral administration of two compounds, paclitaxel and Compound A, to a subject in need of treatment.
According to the patent claims, the method includes the oral administration of paclitaxel at a specific dosage of about 205 mg/m2 to the subject once a day and for three times a week. Additionally, Compound A is orally administered to the subject once a day and for one to three times a week, prior to the administration of paclitaxel. The dosage of Compound A is not specified in the first claim.
Claim 2 states that paclitaxel can be administered on consecutive days, while claim 3 specifies that Compound A can be administered at a dosage of about 15 mg. Claim 4 mentions the oral administration of Compound A for three times a week, and claim 5 suggests the administration of Compound A on consecutive days. Claim 6 combines the administration of Compound A at a dosage of about 15 mg and for three times a week.
Claims 7 and 8 introduce the oral administration of paclitaxel and Compound A on consecutive days, respectively. Claim 9 specifies that Compound A should be administered about an hour prior to paclitaxel.
The patent also includes claims related to the treatment of cutaneous angiosarcoma, a specific type of angiosarcoma. Claim 10 states that the method can be used to treat cutaneous angiosarcoma.
The patent further describes an alternative method for treating angiosarcoma in claim 11. This method involves the oral administration of paclitaxel at a dosage of about 205 mg/m2 to the subject once a day and for three times a week for a first duration. Then, a second dosage of paclitaxel, less than 205 mg/m2, is administered once a day and for three times a week for a second duration. Compound A is administered prior to the paclitaxel in this method as well.
Claims 12 and 13 specify the second dosage of paclitaxel as about 165 mg/m2 and about 130 mg/m2, respectively. Claim 14 adds the oral administration of Compound A at a dosage of about 15 mg and for three times a week to this alternative method.
Lastly, claim 16 introduces a method that includes the oral administration of paclitaxel at a dosage of about 205 mg/m2 for a first duration, a second dosage less than 205 mg/m2 for a second duration, and a third dosage less than the second dosage for a third duration. Compound A is administered prior to the paclitaxel in this method as well.
Claims 17 and 18 specify the second and third dosages of paclitaxel as about 165 mg/m2 and about 130 mg/m2, respectively. Claim 19 adds the oral administration of Compound A at a dosage of about 15 mg and for three times a week to this method.
All of the described methods in the patent claims are intended for the treatment of angiosarcoma, with specific mentions of cutaneous angiosarcoma in some claims. The patent provides detailed instructions for the oral administration of paclitaxel and Compound A, potentially offering new treatment options for patients with angiosarcoma.
To know more about GlobalData’s detailed insights on Athenex, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
